Hospital for Special Surgery

Refer A Patient

Osteogenesis Imperfecta

Clinical Trials

A Randomized Double Blind Placebo Controlled Multi-Center Parallel Group Study of One Year Duration Followed by Two Years of open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate

© Hospital for Special Surgery. 535 East 70th Street, New York, NY 10021